Overview

• Tulsi-28X, combining Wharton’s Jelly mesenchymal stem cells with their native exosomes, achieved complete reversal of liver fibrosis with zero mortality in animal models.
• Collaborators including Indiana University’s Dr. Naga Chalasani and PGIMER’s Dr. Ajay Duseja oversaw trials that contrasted starkly with control groups showing 14% reversal and 43% mortality.
• Originally conceptualized in the United States and fully developed over three years at ASPIRE-BioNEST in Hyderabad, the therapy is the world’s first dual stem cell–exosome biologic.
• Key findings were showcased at the AASLD 2024 Liver Conference in San Diego and accepted for publication in the Journal of Regenerative Medicine.
• Tulsi Therapeutics has secured a partnership with Nizam’s Institute of Medical Sciences to navigate regulatory approvals and design its inaugural human clinical trials.